References
1
Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015;7:102-10.
2
Dirikoç M, Uncu D. Mide kanserinde neoadjuvan ve adjuvan tedavi. Coşkun F, Dinç T, editörler. Mide Kanseri ve Tedavisi. 1. Baskı. Ankara: Türkiye Klinikleri; 2022. p.69-73.
3
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice 177 Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):38-49.
4
https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (15 Agust 2022)
5
Grizzi G, Petrelli F, Di Bartolomeo M, Texeira Moraes M, Luciani A, Passalacqua R, et al. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Gastric Cancer 2022;25:982-7.
6
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
7
Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210-8.
8
Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-21.
9
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8.
10
Wang X, Li S, Sun Y, Li K, Shen X, Xue Y, et al. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer 2021;21:20.
11
Hofheinz R, Hegewischbecker S, Kunzmann V, Thusspatience PC, Fuchs M, Homann N, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2- positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer 2021;149:1322-31.
12
Al-Batran SE, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, et al. Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma. Ann Oncol 2020;31:4.
13
Bang Y, Cutsem EV, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, et al. Keynote-585: phase 3 study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol 2019;15:943-52.
14
Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Gastric Cancer 2019;22:245-4.
15
Li J, Zhao Q, Ge X, et al. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. BMC Surg 2021;21:137.
